U.S. biopharma company AbbVie has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ) for the treatment of adult patients with moderately to severely active Crohn’s disease. “Crohn’s disease can be debilitating and have a significant impact on a person’s daily life,” […]

Spanish biopharma company Oryzon Genomics, S.A. is starting a preclinical collaboration with the CMT Research Foundation (CMTRF), a U.S.-based patient-led, non-profit organization focused on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease, to explore Oryzon’s histone deacetylase 6 (HDAC6) inhibitors. HDAC6 inhibitors have been previously described as potentially effective treatments for CMT. Oryzon has recently […]